Fig. 2From: Sustained benefit from combined plasmapheresis and allogeneic mesenchymal stem cells transplantation therapy in systemic sclerosisEvaluation of variables associated with interstitial lung disease (ILD) in three patents with systemic sclerosis before mesenchymal stem cell transplantation (MSCT), and at 6 months and 12 months after MSCT. a Diffusing capacity of the lung for carbon monoxide (DLco). b Forced vital capacity (FVC). *P < 0.05. Pts patientsBack to article page